GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Cash, Cash Equivalents, Marketable Securities

AbbVie (AbbVie) Cash, Cash Equivalents, Marketable Securities : $12,816 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Cash, Cash Equivalents, Marketable Securities?

AbbVie's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($8,766.00 Mil) to Sep. 2023 ($13,290.00 Mil) but then stayed the same from Sep. 2023 ($13,290.00 Mil) to Dec. 2023 ($12,816.00 Mil).

AbbVie's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($9,830.00 Mil) to Dec. 2022 ($9,229.00 Mil) but then increased from Dec. 2022 ($9,229.00 Mil) to Dec. 2023 ($12,816.00 Mil).


AbbVie Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for AbbVie's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cash, Cash Equivalents, Marketable Securities Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39,924.00 8,479.00 9,830.00 9,229.00 12,816.00

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,229.00 6,722.00 8,766.00 13,290.00 12,816.00

AbbVie Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


AbbVie  (NYSE:ABBV) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


AbbVie Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of AbbVie's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (AbbVie) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Cash, Cash Equivalents, Marketable Securities
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092